Message_id,From,Time_stamp,Text
<21529551.1075860837153.JavaMail.evans@thyme>,everitt_mary_j@lilly.com,2001-11-29 14:30:50,Chugai Cc You may recall that Lilly entered into a joint venture with Chugai in to gain assistance with developing a number of Lilly compounds in Japan and as an opportunity to work closely with Chugai as a prelude to acquiring a significant interest in the company As we discussed in June it became clear that Lilly would not acquire such interest in Chugai and we no longer need Chugais help with clinical development Therefore we decided to terminate the joint venture Attached to this message is a copy of the press release Chugai will issue tomorrow morning regarding the dissolution of the joint venture and a related amendment to the agreement under which Chugai will comarket raloxifene Please do not hesitate to call me if you have any questions in this regard Alecia A DeCoudreaux CLCR Release Eng final versiondoc
